Loading this company
Loading this company
Too wide to call. Our lenses land between £61.68 and £223.73, which is too broad to say where today’s price sits in it.
£123.34GBP down −£1.12 (−0.90%)
Quoted · Prices are delayed.
Nothing we can cite explains today’s move for this company.
Our range from 4 models, on today’s numbers
£61.68–£223.73
What the price needs: revenue growth of 4.4%/yr for 5 years (our model assumes 5.2%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price £123.34Priced · Prices are delayed.
Our forward range over 12 months is part of Pro. See plans
Analysts’ mean target
£15,792.03 across 22 analysts
The high and low of the analyst range is part of Pro. See plans
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in United Kingdom. The company employs roughly 96,100 people.
Prices are delayed. The feed does not say when these figures were taken.
No filings or corporate activity on file in the recent window.
No recent headlines we can cite for this company.
No insider filings for this company in the recent window.
Not investment advice. TickerWorth Score is a model output.
The score, the fair value and the reverse DCF are free on every company. Pro lets you change growth, margin and the discount rate yourself, see every valuation lens and its working, and download the model. Start a 7-day free trial — a card is required and you can cancel any time before it ends. $99 a year, or $14.99 monthly.